UY33925A - Inhibidores tricíclicos de quinasas - Google Patents

Inhibidores tricíclicos de quinasas

Info

Publication number
UY33925A
UY33925A UY0001033925A UY33925A UY33925A UY 33925 A UY33925 A UY 33925A UY 0001033925 A UY0001033925 A UY 0001033925A UY 33925 A UY33925 A UY 33925A UY 33925 A UY33925 A UY 33925A
Authority
UY
Uruguay
Prior art keywords
tricyclic
quinase
inhibitors
quinase inhibitors
página
Prior art date
Application number
UY0001033925A
Other languages
English (en)
Spanish (es)
Inventor
Tong Yunsong
Thomas D Penning
Alan P Florjancic
Miyashiro Julie
Keith W Woods
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of UY33925A publication Critical patent/UY33925A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
UY0001033925A 2011-02-28 2012-02-27 Inhibidores tricíclicos de quinasas UY33925A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161447405P 2011-02-28 2011-02-28

Publications (1)

Publication Number Publication Date
UY33925A true UY33925A (es) 2012-09-28

Family

ID=46000328

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033925A UY33925A (es) 2011-02-28 2012-02-27 Inhibidores tricíclicos de quinasas

Country Status (11)

Country Link
US (1) US8710065B2 (enExample)
EP (1) EP2681221B1 (enExample)
JP (1) JP5886326B2 (enExample)
CN (1) CN103703005A (enExample)
AR (1) AR085502A1 (enExample)
CA (1) CA2827648A1 (enExample)
ES (1) ES2587514T3 (enExample)
MX (1) MX340402B (enExample)
TW (1) TWI532742B (enExample)
UY (1) UY33925A (enExample)
WO (1) WO2012161812A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
WO2015029447A1 (ja) * 2013-08-30 2015-03-05 興和株式会社 光学活性カルビノール化合物の製造方法
GB201322602D0 (en) * 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
US10300055B2 (en) 2014-04-10 2019-05-28 Dalhousie University Treatment of parkinson's disease through ARFGAP1 inhibition
EP3549582B1 (en) 2014-08-29 2024-10-30 The Board of Regents of The University of Texas System Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10703759B2 (en) 2016-11-16 2020-07-07 Impact Therapeutics, Inc 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones
JP6717457B2 (ja) * 2017-01-23 2020-07-01 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Wee1阻害剤としての1,2−ジヒドロ−3H−ピラゾロ[3,4−d]ピリミジン−3−オン誘導体
CN110678169A (zh) 2017-03-31 2020-01-10 西雅图遗传学公司 Chk1-抑制剂与weel-抑制剂的组合
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN110914277B (zh) * 2017-07-10 2022-08-09 上海瑛派药业有限公司 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
CA3071795A1 (en) * 2017-08-04 2019-02-07 Bayer Aktiengesellschaft 6-phenyl-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
CN107821390A (zh) * 2017-10-13 2018-03-23 南京扬子鸿利源化学品有限责任公司 一种甲基磺草酮油悬浮剂及其制备方法
SG11202003974XA (en) 2017-11-01 2020-05-28 Shijiazhuang Sagacity New Drug Development Co Ltd Macrocyclic compound serving as weel inhibitor and applications thereof
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
CN108727249A (zh) * 2018-07-07 2018-11-02 台州学院 3-二氟甲基哌啶盐酸盐及其衍生物的合成方法
KR20210066839A (ko) * 2018-09-27 2021-06-07 베타 파머수티컬 컴퍼니 리미티드 Fgfr4 저해제 및 그것의 용도
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US12180184B2 (en) 2018-10-26 2024-12-31 Wuxi Biocity Biopharmaceutics Co., Ltd. Pyrimidopyrazolone derivative as Wee1 inhibitor and use thereof
TWI750573B (zh) 2019-02-01 2021-12-21 德商拜耳廠股份有限公司 1,2,4-三-3(2h)-酮化合物
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
SI3964510T1 (sl) 2019-04-30 2024-10-30 Wuxi Biocity Biopharmaceutics Co., Ltd. Kristalna oblika WEE1 inhibitorske spojine in njena uporaba
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CN112442049A (zh) * 2019-09-03 2021-03-05 微境生物医药科技(上海)有限公司 作为Wee1抑制剂的嘧啶衍生物
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US20240010655A1 (en) * 2019-10-16 2024-01-11 Impact Therapeutics (Shanghai), Inc Dihydroimidazo pyrimido pyrimidinone compound
JP7832891B2 (ja) 2019-12-04 2026-03-18 インサイト・コーポレイション Fgfr阻害剤の誘導体
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3180664A1 (en) 2020-06-17 2021-12-23 Yuli Xie Pyrazolo[3,4-d]pyrimidine-3-one derivative as wee-1 inhibitor
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
CN116888107B (zh) * 2021-02-19 2026-04-21 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
KR20240004539A (ko) * 2021-04-30 2024-01-11 위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드 Wee-1 억제제로서의 축합 고리 화합물, 그를 위한 제조 방법 및 그의 용도
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
EP4431511A4 (en) * 2021-11-09 2025-10-15 Hangzhou Glubio Pharmaceutical Co Ltd WEE1 PROTEIN KINASE DEGRADING AGENT AND ITS USE
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
CN119039287A (zh) * 2023-05-29 2024-11-29 中国药科大学 一类四氢吡啶并嘧啶酮衍生物及其制备方法与应用
KR20250136774A (ko) * 2024-03-08 2025-09-16 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1687284B1 (en) 2003-07-25 2008-10-29 Novartis AG p-38 KINASE INHIBITORS
US20050070554A1 (en) * 2003-08-27 2005-03-31 Amgen Inc. Substituted heterocyclic compounds and methods of use
US20050250836A1 (en) * 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
AR058277A1 (es) 2005-12-09 2008-01-30 Solvay Pharm Gmbh N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion
US8299080B2 (en) * 2006-12-13 2012-10-30 Aska Pharmaceutical Co., Ltd. Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor
WO2009054332A1 (ja) * 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
WO2009151997A1 (en) 2008-06-12 2009-12-17 Merck & Co., Inc. Process for producing bicycloaniline derivatives
AU2009325398A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative

Also Published As

Publication number Publication date
JP2014506929A (ja) 2014-03-20
US20120220572A1 (en) 2012-08-30
MX340402B (es) 2016-07-07
CN103703005A (zh) 2014-04-02
WO2012161812A1 (en) 2012-11-29
TWI532742B (zh) 2016-05-11
MX2013009873A (es) 2014-03-12
US8710065B2 (en) 2014-04-29
CA2827648A1 (en) 2012-11-29
EP2681221B1 (en) 2016-05-18
JP5886326B2 (ja) 2016-03-16
ES2587514T3 (es) 2016-10-25
EP2681221A1 (en) 2014-01-08
AR085502A1 (es) 2013-10-09
TW201247675A (en) 2012-12-01

Similar Documents

Publication Publication Date Title
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34559A (es) Inhibidores de bromodominios
UY34374A (es) Benzilindazoles sustituidos
UY34004A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
UY34034A (es) Triazolopiridinas
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY34145A (es) Compuestos inhibidores de metaloenzimas
UY34550A (es) Bencilpirazoles sustituidos
UY34146A (es) Compuestos inhibidores de metaloenzimas
UY34039A (es) Compuestos fungicidas
UY34515A (es) Triazolopiridinas sustituidas
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY33978A (es) Piridinonas bicíclicas nuevas.
UY33958A (es) Inhibidores de la glucosilceramida sintasa
UY34648A (es) Amidas como inhibidores de pim
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
UY4149Q (es) Golosina para mascota
UY34763A (es) Inhibidores de la agregación plaquetaria
UY33930A (es) Inhibidores novedosos de quinasas
UY34502A (es) Arilos y heteroarilos bicíclicos inhibidores de los canales de sodio
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
UY34523A (es) Derivados de betulina
UY34817A (es) Tienopirimidinas
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201019